Adjunctive therapy for multidrug-resistant bacterial infections: type III secretion system and efflux inhibitors.
Adjunctive therapy for multidrug-resistant bacterial infections: type III secretion system and efflux inhibitors.
复制标题
DOI：
10.1016/j.drudis.2021.03.031
复制
发表时间：
2021-04
影响因子：
7.4
通讯作者：
D. Moir;T. Opperman;Z. Aron;T. Bowlin
中科院分区：
文献类型：
--
作者：
D. Moir;T. Opperman;Z. Aron;T. Bowlin
The increasing prevalence of multidrug-resistant (MDR) bacterial infections has created a crucial need for new therapeutics that avoid or minimize existing resistance mechanisms. In this review, we describe the development of novel classes of small-molecule adjunctive agents targeting either a bacterial virulence factor, thePseudomonas aeruginosatype III secretion system (T3SS), or an intrinsic resistance factor, resistance-nodulation-cell division superfamily (RND) efflux pumps of theEnterobacteriaceae. These agents are designed to be administered with antibacterials to improve their efficacy. T3SS inhibition rescues host innate immune system cells from injection with bacterial toxins, whereas RND efflux pump inhibition increases antibiotic susceptibility, in both cases improving the efficacy of the combined antibacterial.
